Cytokinetics (Cytokinetics) Long-Term Capital Lease Obligation : $118.55 Mil (As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Cytokinetics Long-Term Capital Lease Obligation?

Cytokinetics's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $118.55 Mil.

Cytokinetics's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 ($122.22 Mil) to Dec. 2023 ($120.43 Mil) and declined from Dec. 2023 ($120.43 Mil) to Mar. 2024 ($118.55 Mil).

Cytokinetics's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($112.23 Mil) to Dec. 2022 ($126.90 Mil) but then declined from Dec. 2022 ($126.90 Mil) to Dec. 2023 ($120.43 Mil).

Cytokinetics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Cytokinetics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytokinetics Long-Term Capital Lease Obligation Chart

Cytokinetics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

2.20

0.44

112.23

126.90

120.43

Cytokinetics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															125.34	123.83	122.22	120.43	118.55

Cytokinetics (NAS:CYTK) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Cytokinetics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Cytokinetics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytokinetics (Cytokinetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (NAS:CYTK) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

KK3A:Germany

Address

350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.cytokinetics.com

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Executives

Robert I Blum	officer: EVP, Corp. Development & CBO	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John T Henderson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Fady Ibraham Malik	officer: SVP Research & Early Dev	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Wendall Wierenga	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Muna Bhanji	director	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Robert Wong	officer: VP, Chief Accounting Officer	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Ching Jaw	officer: SVP Finance & CFO	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Sandford D Smith	director	C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
B Lynne Parshall	director	2855 GAZELLE COURT, CARLSBAD CA 92010
Santo J Costa	director
Kaye Edward M. Md	director	3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Robert Arthur Harrington	director	C/O CYTOKINETICS, INCORPORATED, 350 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Mark A Schlossberg	officer: SVP - Legal & General Counsel	C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
David Cragg	officer: V.P., Human Resources	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
L Patrick Gage	director	C/O NEOSE TECHNOLOGIES, 102 WITMER RD, HORSHAM PA 19044